The PC gaming segment is projected to grow at an average annual revenue rate of 6.6% from 2025 to 2028, while the console segment is expected to grow at 4.4% annually. By 2028, combined revenue from console and PC gaming is anticipated to exceed .7 billion, with PC games accounting for over half of this total for the first time in 13 years, up from an estimated .3 billion at the end of 2025. Microtransactions will contribute 48% of PC revenue in 2025, while game sales will make up half of console revenue. In 2025, 20 games generated two-thirds of console revenue across major markets. The PC gaming audience is expected to reach 966 million by the end of 2026 and surpass one billion by 2028, with significant growth from China and other Asian countries. The console gaming audience is projected to grow from 662 million in 2026 to 688 million by 2028. In 2025, gamers spent 1% less time on console and PC games compared to 2024, dedicating 48% of their gaming time to PCs, 34% to PlayStation, and 18% to Xbox. Over half (54%) of playtime in 2025 was on games older than six years, with 33% on titles aged one to five years, and only 13% on new releases. There is a trend among PC users towards less mainstream titles, with 42% of playtime in 2025 spent on games outside the top 20. Popular gaming IPs in 2025 included Roblox, Fortnite, and Call of Duty.
PC game revenue growth outpaced console revenue growth in 2025, marking a shift in the gaming industry. Newzoo forecasts a 6.6% annual growth rate for PC revenue from 2025 to 2028, compared to 4.4% for consoles, with PC revenue expected to surpass console revenue by 2028. However, 84% of spending by Chinese players is on domestically produced games, posing challenges for external developers. Additionally, 66% of Steam users engage in a language other than English. A memory and storage supply crisis may threaten continued PC revenue growth and impact the broader consumer electronics sector, potentially leading to shortages and price increases by 2028.
Waystar Holding is integrating EDB Postgres AI into its healthcare data operations to enhance secure and scalable transaction processing, aiming to consolidate payment and claims workloads in a regulated environment. The company processes healthcare payments for about half of the U.S. patient population, making data reliability and control crucial. The transition to EDB Postgres AI addresses the need to manage sensitive health information amid increasing electronic claims and digital payments. Waystar's stock price is currently at US, approximately 43% below the analyst target of US, and 35.8% below its estimated fair value, with an 18.9% decline over the past 30 days. The rollout of EDB Postgres AI is expected to impact uptime, client acquisitions, and operational efficiency, but there are execution risks associated with migrating critical workloads to a new database platform.
ClickHouse has secured 0 million in a Series D funding round led by Dragoneer Investment Group, with participation from investors such as Bessemer Venture Partners, GIC, and others. The funding will support global expansion and product development, focusing on AI infrastructure and application monitoring. ClickHouse currently has over 3,000 customers on its ClickHouse Cloud platform, with an annual recurring revenue growth exceeding 250% year over year. Recent adopters include Capital One, Lovable, and Airwallex, alongside established clients like Meta and Tesla. ClickHouse has acquired Langfuse, an open-source platform for LLM observability, and introduced a native Postgres service for integrating transactional workloads with its analytical engine. The company is also expanding its ecosystem and geographic reach through partnerships, including one with Japan Cloud and collaboration with Microsoft Azure.
Microsoft's CEO Satya Nadella highlighted that over 150 million users are engaging with its Copilot assistant, which aims to enhance productivity in various sectors. However, there are challenges in the enterprise market, with clients hesitant to adopt Copilot licenses and some wanting to reduce their licenses. Copilot, launched as an add-on to Microsoft 365, helps with tasks like summarizing emails and creating presentations. Microsoft has invested heavily in AI, particularly through its Azure cloud infrastructure, which reported a 40% revenue growth. Competing tech companies like Adobe, Google, Salesforce, and Workday are also targeting the enterprise AI market. Despite skepticism, over 90% of Fortune 500 companies use Microsoft 365 Copilot, and some organizations have purchased large numbers of licenses. To encourage adoption, Microsoft plans to introduce a new tier for Microsoft 365 Copilot Business and has offered discounts in the past. Companies like Land O'Lakes and Pearson have successfully integrated Copilot into their operations. Microsoft is also collaborating with Anthropic to enhance its AI offerings. Daily usage of Copilot among commercial sales and support staff has increased, indicating growing internal traction.
Tandem Diabetes Care has received FDA clearance for the Android version of the Tandem Mobi mobile app, set for limited release in December 2025 and broader availability in early 2026. This app will enhance accessibility to Tandem’s automated insulin delivery system for users with compatible Android smartphones. The company plans to launch the t:slim X2’s integration with Abbott’s FreeStyle Libre 3 Plus CGM sensor in October 2025, aiming to attract more continuous glucose monitoring users. Analysts project Tandem Diabetes Care could achieve .2 billion in revenue and .4 million in earnings by 2028, assuming a 7.5% annual revenue growth rate. Fair value estimates for the stock range from .64 to .57 per share, indicating a potential downside from its current market price.
Tandem Diabetes Care received FDA clearance for the Android version of its Tandem Mobi mobile app, allowing Android users to manage insulin delivery through its automated insulin pump system. The integration of Tandem's t:slim X2 with the Abbott FreeStyle Libre 3 Plus sensor was highlighted as a significant advancement in enhancing device connectivity. The company projects .2 billion in revenue and .4 million in earnings by 2028, requiring an annual revenue growth rate of 7.5% and an earnings increase from -5.5 million. Community fair value estimates for Tandem Diabetes Care range from .64 to .72.
In November 2025, Tandem Diabetes Care received FDA clearance for the Android version of its Tandem Mobi mobile app, allowing Android smartphone users in the U.S. to access its automated insulin delivery system. This development is expected to enhance patient engagement and support the company's growth in the insulin pump market. Tandem Diabetes Care is projected to reach .2 billion in revenue and generate 0.4 million in earnings by 2028, assuming a 7.5% annual growth rate. The fair value estimate for the company's stock ranges from .64 to [openai_gpt model="gpt-4o-mini" prompt="Summarize the content and extract only the fact described in the text bellow. The summary shall NOT include a title, introduction and conclusion. Text: In November 2025, Tandem Diabetes Care achieved a significant milestone with the FDA's clearance for the Android version of its Tandem Mobi mobile app. This development opens the door for a broader range of users, particularly Android smartphone owners in the United States, to access its automated insulin delivery system.
Expanding Horizons
The introduction of the Tandem Mobi app on Android devices not only enhances patient engagement but also paves the way for increased adoption of Tandem's innovative insulin delivery technology. This strategic move is expected to support the company's growth narrative in a competitive and rapidly evolving market landscape.
Investors looking to stake their claim in Tandem Diabetes Care must have confidence in the company's capacity to drive the adoption of its insulin delivery solutions. The recent FDA approval for the Android app is a positive catalyst for attracting new patients. However, it does not entirely mitigate the ongoing risks associated with flat renewal rates and intensified competition within the U.S. insulin pump sector.
By integrating the Tandem Mobi app with Android, Tandem Diabetes Care is poised to reach a wider audience, thereby enhancing flexibility in patient engagement. This milestone aims to address existing growth challenges, even as the company navigates rising execution risks linked to the transformation of its commercial organization and the complexities of entering new channels and international markets.
Despite the promising expansion of product access, investors should remain cautious, as immediate benefits may not fully counterbalance the inherent risks associated with such rapid growth.
Looking ahead, Tandem Diabetes Care is projected to reach .2 billion in revenue and generate .4 million in earnings by 2028, assuming an annual revenue growth rate of 7.5% and a substantial earnings increase from current losses. This optimistic outlook suggests a fair value estimate of .64 per share, indicating a potential 14% upside from its current market price.
Community sentiment on Tandem's fair value varies significantly, with estimates ranging from .64 to .38 per share. While differing opinions reflect diverse expectations for the company's future, the execution risks tied to its commercial transformation remain a critical factor that could influence outcomes. Investors are encouraged to consider multiple perspectives when evaluating Tandem's potential.
For those interested in delving deeper into Tandem Diabetes Care's financial landscape, a comprehensive analysis highlighting key rewards and risks is readily available. This resource simplifies the evaluation of the company's overall financial health, providing a clear visual summary for prospective investors.
As the market continues to evolve, staying informed about developments in Tandem Diabetes Care and other related stocks is essential. The landscape is dynamic, and timely insights can be the key to making informed investment decisions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology, and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives or financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned." max_tokens="3500" temperature="0.3" top_p="1.0" best_of="1" presence_penalty="0.1" frequency_penalty="frequency_penalty"].38 per share, with a potential 14% upside from its current market price.
Dole Food Company is launching a global campaign called “Make the World a Healthier Place” in collaboration with Minecraft, running from October 2025 to March 2026, aimed at promoting healthier lifestyles and nutrition awareness among families in North America and Europe. This marks Dole's first simultaneous marketing effort across these regions using a major digital platform. The company recently completed a .9 million follow-on equity offering to improve its balance sheet flexibility. Dole projects revenue of .1 billion and earnings of million by 2028, with an expected annual revenue growth rate of 1.4%. Current fair value estimates for Dole range from .41 to .34, reflecting varied analyst outlooks amid ongoing margin pressures and earnings volatility.
